

REPAIR investments focused on most urgent multi-drug resistant infections

Bacteria (WHO category)	WHO (2017)	CDC (2019)
<i>Acinetobacter baumannii</i> , carbapenem-R	Critical	Urgent
<i>Pseudomonas aeruginosa</i> , carbapenem-R	Critical	Serious
<i>Enterobacteriaceae</i> , carbapenem-R, 3 rd -gen cep-R (ESBL+)	Critical	Urgent (CRE) Serious (ESBL+)
<i>Enterococcus faecium</i> , vancomycin-R	High	Serious
<i>Staphylococcus aureus</i> , methicillin-R, vancomycin-I/R	High	Serious
<i>Helicobacter pylori</i> , clarithromycin-R	High	
<i>Campylobacter</i> spp., drug-R	High	Serious
<i>Salmonellae</i> spp., drug-R	High	Serious
<i>Neisseria gonorrhoeae</i> , 3 rd -gen cep-R, drug-R	High	Urgent
<i>Streptococcus pneumoniae</i> , drug-R	Medium	Serious
<i>Haemophilus influenzae</i> , ampicillin-R	Medium	
<i>Shigella</i> spp., drug-R	Medium	Serious
<i>Clostridium difficile</i>		Urgent
<i>Candida auris</i>		Urgent
<i>Candida</i> spp., drug-R		Serious
<i>M. tuberculosis</i>		Serious
Group A <i>Streptococcus</i>		Concerning
Group B <i>Streptococcus</i>		Concerning

